Jared Lunceford
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, Bladder and Urothelial Cancer Treatments
Most-Cited Works
- → Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer(2015)6,153 cited
- → IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade(2017)3,762 cited
- → Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy(2018)2,281 cited
- → Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial(2016)1,717 cited
- → Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study(2004)1,673 cited
- → Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial(2016)1,123 cited
- → T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028(2018)979 cited
- → Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes(2006)880 cited
- → Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma(2016)667 cited
- → PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer(2017)593 cited